<a href="https://laohu8.com/S/NNVC">NanoViricides Inc.</a> Announces New Compensation Agreements, Extends President Dr. Anil Diwan's Contract with $400,000 Salary and Equity Incentives
NanoViricides Inc. has announced updated employment agreements for two key executives. Dr. Anil R. Diwan will continue as President under a contract extension effective July 1, 2025, and has been granted 10,204 shares of Series A Preferred Stock, vesting quarterly from September 30, 2025, through June 30, 2026. Should Dr. Diwan be terminated without cause, he will receive six months' salary as severance along with continued benefits. Chief Financial Officer Meeta Vyas has also extended her contract for one year starting July 1, 2025, maintaining her monthly base compensation of $10,800 and 129 shares of Series A Preferred Stock per month. Additionally, Ms. Vyas will now be reimbursed for up to 50% of her health insurance costs, capped at $2,500 per month.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-095676), on October 01, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。